XHKG6893
Market cap36mUSD
Dec 12, Last price
0.26HKD
Name
Hin Sang Group (International) Holding Co Ltd
Chart & Performance
Profile
Hin Sang Group (International) Holding Co. Ltd., together with its subsidiaries, primarily engages in the manufacture, marketing, and sale of healthcare products primarily targeting at children in Hong Kong and Mainland China. The company operates through four segments: Product Development, Brand Development and Management, Trading of Goods, and Healthcare. The Product Development segment develops and sells personal care products, household products, and health supplements under the Hin Sang, Tai Wo Tong, Cheers Smart, Care Plus, Shuang Long, and King's Antiseptic brand names. The Brand Development and Management segment engages in marketing, selling and distribution, logistics, and delivery services of personal care products under the Pahmi, Enear, Vcnic, Zici, and Sunew brand names; and manages and develops brands for its brand proprietors. The Trading of Goods segment engages in the distribution and sale of skin care products, personal care products, and household products purchased from various authorized dealers, independent traders, manufacturers, parallel importers, and suppliers. The Healthcare segment provides Chinese medical healthcare related services for mothers and children; develops mother and child related health products; and hospital, medical center, and related services. It is also involved in the trading of skin care, personal care, and slimming products; and property holding business. The company sells its products in Hong Kong, as well as sells through a network of distributors in the People's Republic of China and Macau. It also sells its products online. The company was founded in 1996 and is headquartered in Tsim Sha Tsui, Hong Kong. Hin Sang Group (International) Holding Co. Ltd. is a subsidiary of Genwealth Group Holding Company Limited.
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | 2015‑03 | |
Income | ||||||||||
Revenues | 92,617 13.70% | 81,460 -32.42% | 120,546 0.93% | |||||||
Cost of revenue | 114,749 | 118,282 | 136,379 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (22,132) | (36,822) | (15,833) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (395) | (55) | 1,687 | |||||||
Tax Rate | ||||||||||
NOPAT | (21,737) | (36,767) | (17,520) | |||||||
Net income | (36,705) -25.84% | (49,491) 315.54% | (11,910) -62.72% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 186,818 | 156,808 | 120,075 | |||||||
Long-term debt | 136,015 | 162,937 | 203,125 | |||||||
Deferred revenue | 160,985 | 199,508 | ||||||||
Other long-term liabilities | (160,985) | (199,508) | ||||||||
Net debt | 256,933 | 282,497 | 279,837 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 6,285 | 402 | 23,992 | |||||||
CAPEX | (665) | (4,195) | (343) | |||||||
Cash from investing activities | (585) | (2,092) | 15,196 | |||||||
Cash from financing activities | (4,871) | (93) | (41,666) | |||||||
FCF | 13,451 | 37,269 | 9,360 | |||||||
Balance | ||||||||||
Cash | 19,351 | 12,440 | 17,577 | |||||||
Long term investments | 46,549 | 24,808 | 25,786 | |||||||
Excess cash | 61,269 | 33,175 | 37,336 | |||||||
Stockholders' equity | (425,096) | 300,606 | 413,028 | |||||||
Invested Capital | 955,523 | 525,059 | 582,978 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 1,091,796 | 1,091,796 | 1,091,796 | |||||||
Price | 0.39 34.48% | 0.29 -46.30% | ||||||||
Market cap | 425,800 34.48% | 316,621 -46.30% | ||||||||
EV | 1,403,946 | 1,342,319 | ||||||||
EBITDA | (5,212) | (18,712) | 4,556 | |||||||
EV/EBITDA | 294.63 | |||||||||
Interest | 16,299 | 14,060 | 12,846 | |||||||
Interest/NOPBT |